… ProQR Therapeutics Announces Results for the Fourth Quarter … said Daniel de Boer, Chief Executive Officer of ProQR. "We have advanced QR-010 through preclinical … the Company's IPO on the Nasdaq Global Market, a grant to ProQR's protection foundation, and increased costs reflecting …
… ProQR to Present its Axiomer® RNA Editing Technology at TIDES … & CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through …
… ProQR In-licenses Worldwide Rights to Ophthalmology Drug … said Daniel A. de Boer, chief executive officer of ProQR. “By acquiring the rights to QR-1123, we have … will be made in equity and others in cash or equity at ProQR’s discretion, and royalties on net sales of 20% through …
… ProQR lizenziert weltweite Rechte für Arzneimittelkandidaten … für die Augenheilkunde von Ionis Pharmaceuticals ProQR erhält die exklusive weltweite Lizenz für IONIS-RHO-2.5 … LEIDEN (Niederlande), Oct. 30, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), ein Unternehmen, das …
… ProQR to Present at 3rd Annual Evercore ISI Virtual … will be accessible from the “Investors & Media” section of ProQR’s website ( www.proqr.com ) under ‘ Events ’. The archived webcast will …
… ProQR Announces Additional Sepofarsen Illuminate Trial … top-line announcement in February 2022 that Illuminate , ProQR’s pivotal Phase 2/3 trial of sepofarsen in CEP290 … scheme by the EMA. About Usher s yndrome t ype 2 a and r etinitis p igmentosa Usher syndrome is the leading cause of …